Esperion Therapeutics, Inc. (ESPR)

Over the last six months, Esperion Therapeutics' stock price has increased by 75.69%. Key events include positive guideline recommendations for Bempedoic Acid, a preliminary FY25 revenue report exceeding estimates, Q1 2025 financial results showing strong growth excluding a one-time payment, increased royalty revenue from Daiichi Sankyo Europe, analyst upgrades, and insider selling activity.

Esperion Therapeutics acknowledges the impact of seasonal market dynamics on US product sales. Demand for their cholesterol-lowering therapies may fluctuate throughout the year, potentially influenced by factors such as patient adherence, healthcare spending cycles, or seasonal health trends.

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for elevated LDL-C. The company's core expertise lies in targeting LDL cholesterol, a key risk factor for heart disease. Major products include NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI, indicated for adult patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Esperion is also developing a triple combination product for commercialization in 2027.

Esperion Therapeutics, Inc. is headquartered in Ann Arbor, Michigan, United States. The company has a global presence with treatments approved in the U.S. and Europe. Esperion is working to enable broad access to its medicines globally through international partnerships and collaborations. Approximately 472,500 patients have been treated with Esperion's therapies in Europe. Esperion has expanded commercial partnerships with CSL Seqirus in Australia and New Zealand. Otsuka Pharmaceutical has submitted for approval of bempedoic acid in Japan, with anticipated approval and national health insurance pricing in the second half of 2025. Neopharm Israel filed for regulatory approval in Q1 2025, expecting approval in early 2026, and Esperion has filed submissions for NEXLETOL and NEXLIZET in Canada, with market approval anticipated in Q4 2025.

Esperion Therapeutics has maintained a generally positive brand reputation, driven by clinical endorsements and financial performance. The recommendation of bempedoic acid in the 2025 ACC Scientific Statement bolsters the company's reputation. Strong financial performance and growth, expanding global reach, and analyst confidence contribute positively to its reputation. No specific negative events significantly impacting Esperion Therapeutics' brand reputation in the past year were found in the search results.

Esperion Therapeutics, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. As of February 4, 2026, the company has 282 institutional owners and shareholders holding a total of 121,186,324 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Two Seas Capital LP. Individual insider owners who hold company stock include Benjamin Halladay, Benjamin Looker, and Sheldon L Koenig.